双示踪剂分子影像显示晚期甲状腺髓样癌肿瘤异质性:揭示SSTR与PSMA导向内放射治疗的诊疗潜力
本文报道一名60岁男性甲状腺髓样癌伴肝、骨及淋巴结转移患者,接受177Lu-DOTATOC肽受体放射性核素治疗2个周期后,68Ga-DOTATOC PET/CT显示多处病灶无摄取。为评估患者是否适合前列腺特异性膜抗原(PSMA)靶向放射性配体治疗,行PSMA PET/CT,发现68Ga-DOTATOC有摄取和无摄取病灶均显示PSMA表达增高。双放射性示踪剂PET/CT可能有助于了解甲状腺髓样癌患者肿瘤异质性的复杂性,并可能为后续治疗决策提供依据。
要点
- 60岁男性甲状腺髓样癌伴肝、骨及淋巴结转移,接受177Lu-DOTATOC肽受体放射性核素治疗。
- 2个周期后68Ga-DOTATOC PET/CT显示多处无摄取病灶。
- PSMA PET/CT显示68Ga-DOTATOC有摄取和无摄取病灶均PSMA表达增高。
核心结论
- 双放射性示踪剂PET/CT可能有助于了解甲状腺髓样癌患者肿瘤异质性的复杂性,并可能为后续治疗决策提供依据。
研究设计与样本
- 病例报告:一名60岁男性甲状腺髓样癌伴肝、骨及淋巴结转移患者,接受177Lu-DOTATOC肽受体放射性核素治疗,2个周期后行68Ga-DOTATOC PET/CT,随后行PSMA PET/CT。
主要发现
- 177Lu-DOTATOC治疗2个周期后,68Ga-DOTATOC PET/CT显示多处无摄取病灶。
- PSMA PET/CT显示68Ga-DOTATOC有摄取病灶和无摄取病灶均PSMA表达增高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We present the case of a 60-year-old man with medullary thyroid carcinoma and hepatic, osseous, and lymph node metastases who underwent peptide receptor radionuclide therapy with 177Lu-DOTATOC. After 2 cycles, 68Ga-DOTATOC PET/CT revealed multiple nonavid lesions. To assess whether the patient would be eligible for prostate-specific membrane antigen (PSMA)-targeted radioligand therapy, a PSMA PET/CT was conducted. PSMA PET/CT identified increased PSMA expression in both 68Ga-DOTATOC-avid and nonavid lesions. As such, dual-radiotracer PET/CT may allow for insights into the complexities of tumor heterogeneity in patients with medullary thyroid carcinoma, which may pave the way for subsequent therapeutic algorithms.
引用
- Hasenauer N, Higuchi T, Deschler-Baier B, et al. Visualization of Tumor Heterogeneity in Advanced Medullary Thyroid Carcinoma by Dual-Tracer Molecular Imaging: Revealing the Theranostic Potential of SSTR- and PSMA-Directed Endoradiotherapy. Clin Nucl Med. 2022. PMID: 35085172. doi:10.1097/RLU.0000000000004082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。